DaVita Delivers First-of-its-Kind Dialysis Treatment in the U.S.
May 13, 2014 | Press Releases
Hemodiafiltration differs from hemodialysis – the country's most common dialysis method – in that hemodiafiltration incorporates the standard hemodialysis process but adds an extra step designed to remove even larger toxin particles, thereby further cleansing a patient's blood. Hemodiafiltration is commonly practiced in Europe but until recently there was no FDA approved device for use in the U.S.
"At DaVita, we are always evaluating ways to improve patient outcomes and experience during dialysis treatments," said Shaun Collard, vice president of clinical operations at DaVita. "We are excited to have the opportunity to be the first U.S. provider to evaluate this treatment."
The evaluation will be performed at DaVita's North Colorado Springs Clinic over a period of six months. During this period DaVita clinical experts will determine whether there are improved outcomes of dialysis treatment and patient quality of life compared to those associated with hemodialysis.
"DaVita has a culture of clinical innovation which has driven second-to-none patient outcomes throughout the country," said Dr. Robert Provenzano, M.D., FACP, vice president in DaVita's Office of the Chief Medical Officer. "We are constantly evaluating the efficacy of kidney care treatments and hemodiafiltration has shown potential benefits internationally."
This evaluation supports DaVita's commitment to clinical leadership. DaVita has improved clinical outcomes for the past 14 consecutive years, benefits of which include fewer hospitalizations, significant savings to taxpayers and a better quality of life for patients.
DaVita and DaVita HealthCare Partners are trademarks or registered trademarks of DaVita HealthCare Partners Inc.